Action 002940 ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Actions

002940

CNE100003GC2

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 02/07/2024 		Varia. 5j. Varia. 1 janv.
15,4 CNY +4,19% Graphique intraday de Zhejiang AngLiKang Pharmaceutical CO.,LTD. +8,53% -29,06%
02/07 Deux médicaments d'Anglikang Pharmaceutical obtiennent le feu vert pour leur commercialisation MT
26/04 Zhejiang AngLiKang Pharmaceutical CO.,LTD. publie ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Anglikang Pharmaceutical's Two Drugs Get Marketing Nod
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 002940
  4. Actualités Zhejiang AngLiKang Pharmaceutical CO.,LTD.
  5. Autres langues